Hepatitis B Treatment in India & UAE — Antiviral Therapy & Liver Care from $300
Hepatitis B treatment in India from $300. Entecavir, tenofovir & pegylated interferon therapy by expert hepatologists. 85% viral suppression. Book with GAF Healthcare.
Estimated cost: $300 – $2,000 · Average stay: 1–3 days
Hepatitis B is a potentially serious liver infection caused by the hepatitis B virus (HBV), transmitted through blood, sexual contact, and perinatally from mother to child. Globally, approximately 296 million people are chronically infected with HBV — making it one of the world's most prevalent chronic infections and a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC). In South Asia (including India) and Southeast Asia, HBV is endemic — predominantly spread by perinatal transmission and horizontal transmission in childhood.
Chronic HBV infection (lasting more than 6 months) follows a natural history that passes through phases: immune tolerance (high viral replication, minimal liver inflammation — typically during childhood in perinatally acquired infection); immune clearance (liver inflammation as the immune system attacks HBV-infected hepatocytes — risk of fibrosis); low replication (inactive carrier state); and reactivation (recurrence of active viral replication — risk of progressive liver disease). A minority of patients progress to liver cirrhosis and its complications (portal hypertension, ascites, variceal bleeding, hepatic encephalopathy, hepatorenal syndrome) or HCC.
India and the UAE have specialist hepatology units with access to the full range of modern antiviral therapies — generic entecavir and tenofovir (highly effective, low-resistance-barrier drugs available at a fraction of branded Western prices in India) and pegylated interferon alfa-2a. India's hepatology programmes deliver international-standard care at accessible costs.
Chronic Hepatitis B Assessment
The assessment of chronic HBV includes: HBV serology (HBsAg, HBeAg, anti-HBe, anti-HBc IgG); HBV DNA quantification (viral load — the primary measure of viral replication activity); liver function tests (ALT, AST, bilirubin, albumin, prothrombin time); full blood count; hepatic elastography (FibroScan or MR elastography — non-invasive measurement of liver stiffness as a surrogate for fibrosis stage); abdominal ultrasound; and alpha-fetoprotein (AFP — HCC surveillance marker, performed 6-monthly in patients at HCC risk: cirrhosis, male > 40, Asian female > 50, family history of HCC).
Treatment thresholds are guided by the EASL, AASLD, or APASL guidelines: antiviral therapy is generally recommended when HBV DNA is elevated (> 2,000 IU/mL or > 20,000 IU/mL in HBeAg-positive disease) combined with elevated ALT (> 1× ULN in HBeAg-negative or > 2× ULN in HBeAg-positive disease), or in any patient with evidence of significant fibrosis (≥ F2) or cirrhosis regardless of viral load.
The treatment goal is sustained viral suppression (HBV DNA undetectable or < 20 IU/mL on antiviral therapy) — which prevents further liver inflammation, allows fibrosis regression, reduces the risk of HCC, and reduces the risk of decompensation in cirrhotic patients.
Hepatitis B Treatment Approaches
Nucleos(t)ide analogue (NA) antiviral therapy is the mainstay of chronic HBV treatment. Entecavir (ETV, 0.5 mg daily for non-cirrhotic; 1 mg daily for lamivudine-experienced or cirrhotic patients) and tenofovir disoproxil fumarate (TDF, 300 mg daily) are the preferred first-line agents — both are oral medications with potent viral suppression and high genetic barrier to resistance. Tenofovir alafenamide (TAF, 25 mg daily) is preferred in patients with renal impairment or osteoporosis (TDF can reduce bone mineral density and is mildly nephrotoxic).
NA therapy achieves HBV DNA undetectability in > 95% of patients within 12 months. It is generally lifelong — stopping NAs risks virological rebound and, in cirrhotic patients, severe hepatitis flares that can precipitate liver failure. Treatment can potentially be stopped in non-cirrhotic HBeAg-positive patients who achieve HBeAg seroconversion (a favourable immune response to HBV) and maintain undetectable HBV DNA for 12 months after seroconversion.
Pegylated interferon alfa-2a (PEG-IFN, weekly subcutaneous injection for 48 weeks) is a finite-duration treatment that achieves a durable off-treatment response in approximately 25–30% of patients — a significantly higher functional cure rate than NAs, but at the cost of significant side effects (flu-like symptoms, fatigue, depression, neutropenia, thyroid dysfunction) and is contraindicated in decompensated cirrhosis, autoimmune conditions, and severe depression. It is preferred in younger patients with mild liver disease, high ALT, and HBeAg positivity.
HCC surveillance (ultrasound and AFP every 6 months) continues lifelong in patients with cirrhosis and in certain high-risk non-cirrhotic patients (male over 40, Asian, family history of HCC) regardless of antiviral therapy.
Procedure Steps
- Full hepatitis B serology panel; HBV DNA quantification; liver function tests; FBC
- Liver elastography (FibroScan); abdominal ultrasound; AFP
- Hepatology consultant review: treatment threshold assessment per guidelines
- Antiviral therapy initiated (ETV or TDF/TAF) or PEG-IFN (selected patients)
- HBV DNA monitoring at 3, 6, 12 months; ALT monitoring quarterly
- HCC surveillance: ultrasound + AFP every 6 months (cirrhotic or high-risk patients)
- Long-term monitoring: annual creatinine, phosphate (TDF); bone density (long-term TDF)
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
USA — $1,500 – $5,000 per year (branded) — Save up to 90%
UK — £500 – £2,000 per year (private) — Save up to 80%
UAE — $800 – $3,000 per year — Save up to 75%
India — $300 – $2,000 per year — Best value
Branded entecavir in the USA costs $700–$1,200 per month. In India, generic entecavir costs $20–$40 per month — a WHO-prequalified, bioequivalent generic that provides identical antiviral activity. Generic tenofovir costs $15–$30 per month in India. The complete annual hepatitis B management package (hepatology consultation, HBV DNA monitoring, FibroScan, ultrasound, AFP, and antiviral medication) costs $500–$2,000 per year in India — compared with $5,000–$15,000 in the USA.
Recovery & Follow-up
Hepatitis B antiviral therapy does not have a 'recovery' in the surgical sense — it is a long-term medical programme. Patients typically feel no side effects from entecavir or tenofovir. Viral load (HBV DNA) becomes undetectable within 3–6 months in most patients. ALT normalises within 6–12 months. FibroScan at 3–5 years documents whether liver fibrosis is regressing (which it does in the majority of patients achieving sustained viral suppression).
Recovery Tips
- Take antiviral medication at the same time every day — do not miss doses, as drug holidays risk viral rebound
- Abstain from alcohol completely — alcohol accelerates HBV-related liver fibrosis
- Avoid potentially hepatotoxic medications (paracetamol in excessive doses, herbal remedies) without medical guidance
- Ensure household contacts and sexual partners are tested for HBV and vaccinated if susceptible
- Attend 6-monthly ultrasound and AFP for HCC surveillance if you have cirrhosis
Risks & Complications
Entecavir and tenofovir are exceptionally safe medications. TDF risks include mild renal tubular toxicity (monitoring creatinine and phosphate annually) and bone density reduction with long-term use (DEXA scan at baseline and every 3 years for long-term TDF users — TAF is preferred if osteoporosis is present). Stopping NAs abruptly risks virological rebound and severe hepatitis flare — particularly dangerous in cirrhotic patients. PEG-IFN risks include flu-like syndrome (managed with paracetamol), fatigue, depression, neutropenia, and thyroid dysfunction (all reversible on stopping the drug).
Why GAF Healthcare
GAF Healthcare connects international hepatitis B patients with India's hepatologists for complete assessment, antiviral treatment initiation, and long-term monitoring programme design. For patients from countries where antivirals are prohibitively expensive, India's generic pharmaceutical industry provides the same active molecules at a fraction of the cost — enabling treatment that may otherwise be unaffordable. We provide a structured HBV management plan including monitoring schedule and prescription for continuation at home.
Frequently Asked Questions
Can hepatitis B be cured?
Hepatitis B cannot currently be 'cured' in the conventional sense for the vast majority of chronically infected patients — the HBV DNA integrates into hepatocyte chromosomes and persists as a circular episome (cccDNA) that current antivirals cannot eliminate. The practical treatment goal is 'functional cure' — loss of HBsAg from the blood (HBsAg seroclearance) with undetectable HBV DNA off-treatment. This occurs spontaneously at approximately 1% per year and in approximately 10–15% of patients treated with PEG-IFN. Ongoing research into novel HBV entry inhibitors, capsid assembly modulators, and RNA interference therapies aims to achieve functional cure at much higher rates.
Is hepatitis B treatment lifelong?
For most patients on nucleoside analogue therapy, treatment is effectively lifelong — particularly for patients with cirrhosis (where stopping is dangerous) and for HBeAg-negative patients (where the rate of durable off-treatment response is very low). For young HBeAg-positive patients who achieve HBeAg seroconversion and subsequent HBsAg loss on NAs, stopping may be appropriate under close monitoring. This is an area where current international guidelines are evolving. PEG-IFN is a finite 48-week treatment that achieves a durable off-treatment response in 25–30% of responders.
Is the hepatitis B vaccine effective if I was exposed to hepatitis B?
The hepatitis B vaccine is a preventive measure for uninfected individuals — it protects against HBV infection by inducing protective antibodies. It cannot treat or cure an established chronic HBV infection. However, household contacts and sexual partners of patients with chronic hepatitis B should be tested and vaccinated (with post-vaccination anti-HBs titre checked to confirm adequate response). Newborns of HBsAg-positive mothers should receive HBV vaccine and HBIG (hepatitis B immune globulin) at birth — a highly effective prophylaxis against perinatal HBV transmission.